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Abstract
Background: Renal cell carcinomas (RCCs) display broad resistance against conventional radio- and chemotherapies,
which is due at least in part to impairments in both extrinsic and intrinsic apoptotic pathways. One important
anti-apoptotic factor that is strongly overexpressed in RCCs and known to inhibit both apoptotic pathways is ARC
(apoptosis repressor with a CARD domain).
Methods: Expression and subcellular distribution of ARC in RCC tissue samples and RCC cell lines were determined by
immunohistochemistry and fluorescent immunohistochemistry, respectively. Extrinsic and intrinsic apoptosis signalling
were induced by TRAIL (TNF-related apoptosis-inducing ligand), ABT-263 or topotecan. ARC knock-down was
performed in clearCa-12 cells using lentiviral transduction of pGIPZ. shRNAmir constructs. Extrinsic respectively intrinsic
apoptosis were induced by TRAIL (TNF-related apoptosis-inducing ligand), ABT263 or topotecan. Potential synergistic
effects were tested by pre-treatment with topotecan and subsequent treatment with ABT263. Activation of different
caspases and mitochondrial depolarisation (JC-1 staining) were analysed by flow cytometry. Protein expression of Bcl-2
family members and ARC in RCC cell lines was measured by Western blotting. Statistical analysis was performed by
Student’s t-test.
Results: Regarding the extrinsic pathway, ARC knockdown strongly enhanced TRAIL-induced apoptosis by increasing
the activation level of caspase-8. Regarding the intrinsic pathway, ARC, which was only weakly expressed in the nuclei
of RCCs in vivo, exerted its anti-apoptotic effect by impairing mitochondrial activation rather than inhibiting p53.
Topotecan- and ABT-263-induced apoptosis was strongly enhanced following ARC knockdown in RCC cell lines.
In addition, topotecan pre-treatment enhanced ABT-263-induced apoptosis and this effect was amplified in ARC-
knockdown cells.
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Conclusion: Taken together, our results are the first to demonstrate the importance of ARC protein in the inhibition of
both the extrinsic and intrinsic pathways of apoptosis in RCCs. In this context, ARC cooperates with anti-apoptotic
Bcl-2 family members to exert its strong anti-apoptotic effects and is therefore an important factor not only in the
therapeutic resistance but also in future therapy strategies (i.e., Bcl-2 inhibitors) in RCC. In sum, targeting of ARC may
enhance the therapeutic response in combination therapy protocols.
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Background
Renal cell cancer (RCC) shows strong resistance to
conventional chemotherapy, especially those with Bcl-
2 overexpression which have even worse prognosis
and poorer therapeutic response. Downregulation of
Bcl-2 increased chemosensitivity in clinical studies in
a wide variety of cancers. In RCC cells the Bcl-2
inhibition combined with cisplatin exerts the thera-
peutic effects of cisplatin providing an attractive
therapeutic strategy in Bcl-2 overexpressing RCCs.
Despite therapeutic efforts, RCC remains highly resist-
ant to systemic chemotherapy [1].
Apoptosis repressor with a caspase recruitment
domain (ARC) is a potent inhibitor of apoptosis that it is
strongly expressed in multiple terminally differentiated
cells (i.e., ganglion cells, skeletal muscle and heart muscle)
[2, 3] as well as solid cancers such as carcinomas, melano-
mas, and gliomas [4–10]. Different expression levels of
ARC have been already observed in different cell lines
(MCF-7 - breast cancer, A-549 - non-small lung cancer,
HT-29 - colon cancer, PC-3 prostate cancer, A-498 - kid-
ney cancer). ARC level was different not only in different
cancer cell types, but also among cell types of same cancer
types [11]. While ARC confers significant beneficial
effects in terminally differentiated cells, such as the
attenuation of myocardial ischemia in cardiomyocytes
[12], neuroprotection [13] and the prevention of acute
liver failure [14, 15], its anti-apoptotic properties in ma-
lignant tumours are detrimental because they protect
against activation of extrinsic as well as intrinsic apop-
totic signals. ARC is a unique protein inhibiting both
the extrinsic (death receptor mediated) and intrinsic
(mitochondrial/ER stress induced) apoptotic pathways.
ARC can inhibit apoptosis almost independently from
the inducing cause, such as death receptor activation,
hypoxia, hydrogen peroxide, oxidative stress, serum
deprivation, ischaemic reperfusion, doxorubicin or γ-
radiation [3, 8, 11, 16, 17]. The fact that ARC inhibits
both, extrinsic and intrinsic apoptotic pathways
interacting with them in a non-homotypic death-fold
manner [16], can provide a growth advantage to cancer
cells. In addition, high level of ARC protein in breast
cancer cells is associated with chemo- and radioresis-
tance [8, 11].
ARC with its CARD binds to death receptors, Fas,
FADD and pro-caspase-8 and inhibits the assembly of
DISC, thus abrogating the extrinsic apoptotic signaling.
In the extrinsic pathway of apoptosis, ARC can directly
bind and inhibit caspase-8 [3], whereas in the intrinsic
pathway, ARC interacts with nuclear p53 to prevent p53
tetramerisation and induce the translocation of p53 to
the cytoplasm, thereby preventing p53 activation [17].
In case of ARC knockdown, assembly of death-inducing
signaling complex (DISC) will be facilitated and spontan-
eous Bax activation will be triggered resulted in apoptosis
[8, 16]. In the cytoplasm and mitochondria, ARC also
binds and inhibits caspase-2 as well as Puma, Bad
and Bax, important pro-apoptotic members of the
Bcl-2 family [18, 19].
Furthermore, as a result of differences in binding affinity
for its interaction partners, ARC is able to modulate the
activation of both the extrinsic and intrinsic pathways of
apoptosis. As a result, Puma releases caspase-8 from its
binding to ARC, which enables caspase-8 to induce
the extrinsic apoptotic pathway [20]. In addition, the
anti-apoptotic role of ARC is even more complex, as
it can inhibit calcium (2+)-induced apoptosis by binding
calcium and prevent the activation c-jun N-terminal kin-
ase (JNK) [14, 21].
One novel and orally bioavailable Bcl-2 inhibitor is
Navitoclax (ABT-263) acting as Bcla-3 homology 3 (BH3)
mimetic. ABT-263 inhibits selectively Bcl-2, Bcl-xl and
Bcl-w in a wide range of human cancer cell lines (i.e.,
small cell lung cancer, ALL, NHL, myeloma). Further-
more, in clinical trials, ABT-263 showed a significant anti-
tumor activity as a monotherapy or in combination with
conventional chemotherapeutic agents (i.e., irinotecan,
erlotinib, 5-FU, paclitaxel etc.) [22, 23]. For example,
ABT-263 in combination with 5-FU enhances significantly
the effects of 5-FU and intensify apoptosis in oesophageal
cancer cell lines. This effect can be explained by inhibition
of YAP-1/SOX-9 axis and Wnt signalling [24].
Furthermore, ABT-263 and paclitaxel combination
showed also a synergistic effect on both paclitaxel sensi-
tive and resistant prostate cancer cell lines by interaction
of ABT-263 and Bcl-xl in both cell lines [25]. ABT-263
disrupts Bcl-2/Bcl-xl interactions with pro-apoptotic
proteins (i.e., Bim) leading to initiation of apoptosis. In
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addition, ABT-263 induces Bax translocation, cyto-
chrome c release leading to apoptosis [26].
Because ARC performs important anti-apoptotic
functions, we previously investigated the expression of
ARC in renal cell carcinomas (RCCs) of the clear cell
type, which are known to be very resistant towards
chemotherapy. These findings demonstrated strong
overexpression of ARC in all RCCs compared to non-
neoplastic renal tissue and therefore proposed an
important anti-apoptotic role for ARC in mediating
the well-known resistance to apoptosis observed in
RCCs [5, 27, 28]. However, it remained unclear which
pathways were functionally impaired following ARC
overexpression in RCCs. Specifically, the role of ARC
in the inhibition of the mitochondrial pathway of
apoptosis, which we and others previously found to
be strongly impaired in RCCs [27, 28], became the
focus of our current interest because reactivation of
this pathway using recently developed targeted thera-
peutic strategies with Bcl-2 inhibitors may prove to
be a promising therapeutic approach.
In this paper, we show for the first time that ARC is
an important anti-apoptotic factor in RCCs of the clear
cell renal cancer and that its effects are mediated
through interference with mitochondrial apoptosis, fur-
ther enhancement of the apoptosis-inhibiting properties
of Bcl-2 family members and inhibition of the extrinsic
pathway. Furthermore, we confirm that targeted therapy
with Bcl-2 inhibitors may represent a promising new
therapeutic approach for RCCs, especially in combin-
ation with DNA-damaging drugs such as topotecan or
other compounds that reduce the protein expression of
anti-apoptotic members of the Bcl-2 family.
Methods
Immunohistochemistry
Immunohistochemistry was performed using the labelled
streptavidin-biotin method. A primary antibody for ARC
(Table 1) was applied to the sections. Visualisation of
this primary antibody was achieved following incuba-
tions with a biotinylated secondary antibody, labelled
streptavidin and diaminobenzidine. Negative controls
were performed by omitting the primary antibody. The
tunica muscularis of the vessels was used as an internal
positive control.
For semiquantitative analysis of ARC-expression cyto-
plasmatic staining was scored from 0 to 12 and nuclear
expression was scored from 0 to 4. For scoring of the
Table 1 Antibodies used for western blot analyses and immunohistochemistry with their sources, dilutions and manufacturers
Protein Source Dilution Manufacturer
Bcl-A1 Mouse, monoclonal 1:500 Santa Cruz, Germany
ARC (IH) Rabbit, poloyclonal 1:2 000 Santa Cruz, Germany
ARC (WB) Rabbit, polyclonal 1:1 000 Thermo Scietific, Germany
β-Actin Mouse, monoclonal 1:10 000 DAKO, Germany
Bad Rabbit, polyclonal 1:1 000 Cell Signalling, Germany
Bak Rabbit, polyclonal 1:1,000 Cell Signalling, Germany
Bax Rabbit, polyclonal 1: 1 000 Cell Signalling, Germany
Bcl-2 Mouse, monoclonal 1:1 000 DAKO, Germany
Bcl-w Rabbit, polyclonal 1:1 000 Santa Cruz, Germany
Bcl-xl Rabbit, polyclonal 1:1 000 Cell Signalling, Germany
Bid Rabbit, polyclonal 1:1 000 Cell Signalling, Germany
Bim Rabbit, polyclonal 1:1 000 Cell Signalling, Germany
Bok Rabbit, polyclonal 1:1 000 Cell Signalling, Germany
GAPDH Rabbit, polyclonal 1:4 000 Sigma, Germany
Mcl-1 Rabbit, polyclonal 1:1 000 Cell Signalling, Germany
Phospho-p44/42 (Thr202/Tyr204) Rabbit, polyclonal 1:1 000 Cell Signalling, Germany
PUMA Rabbit, polyclonal 1:1 000 Cell Signalling, Germany
α-Tubulin Mouse, monoclonal 1:10 000 Sigma, Germany
Secondary antibodies
Rabbit Goat, polyclonal 1:10 000 LI-COR, Germany
Mouse Goat, polyclonal 1:10 000 LI-COR, Germany
Rabbit, AlexaFluor 514 Goat, polyclonal 1:1 000 Invitrogen, Germany
mMouse, AlexaFluor 594 Goat, polyclonal 1:1 000 Invitrogen, Germany
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cytoplasmatic as well as nuclear ARC-expression the
amount of positive cells was subdivided as follows: 0
(missing reaction in all cells), 1 (positive reaction in less
than 10% of the cells), 2 (positive reaction in 10–50%), 3
(positive reaction in 50–80%) or 4 (positive reaction in
more than 80%). For cytoplasmatic scoring this first nu-
merical value was multiplied with the mean intensity of
cytopasmatic ARC-staining: 1 (weak staining signal), 2
(moderate staining signal) or 3 (strong staining signal).
Cell culture
RCC cell lines and HEK293T cells were grown at 37 °C
in an atmosphere containing 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% foetal
bovine serum (FCS), 2 mM glutamine, 100 U/ml penicillin
and 100 μg/ml streptomycin. Transduced RCC cells were
maintained in the medium described above supplemented
with 2 μg/ml puromycin. For treatment, cells were
exposed to the following substances dissolved in culture
medium for defined periods of time: 0.1 to 10 μg/ml
topotecan (Hycamtin®, GSK, Buehl, Germany), 100 ng/ml
superkillerTrail (EnzoLifeScience, Lörrach, Germany) or
10 or 20 μM ABT263 (Navitoclax®, Selleckchem, Texas,
USA) or 50 μM UO126 (Selleckchem). The corresponding
negative controls were prepared with the appropriate
solvent (PBS or DMSO).
Lentiviral transduction and ARC knockdown with pGIPZ
shRNAmir constructs
HEK 293 T cells were transfected using 45 μg polyethy-
leneimine (Sigma) with 5 μg of the HIV1 helper plasmid
pCD/NL-BH to express HIV1 gag/pol/rev (pCD/NL-BH)
[29], 5 μg of the envelope vector pczVSV-G [30] and
5 μg of the pGIPZ ARCshRNA plasmid (Thermo Scien-
tific, Schwerte, Germany). As a control, we used the
pGIPZ non-silencing shRNA plasmid carrying a scram-
bled shRNA. Viral supernatants were harvested 48 h after
transfection, filtered and used to transduce clearCa-12
RCC cells. The selection of cells with integrated copies of
the shRNA-expressing vector was accomplished using
puromycin (2 μg/ml) in the culture media. TurboGFP,
which is also encoded by the pGIPZ plasmid, enabled vis-
ual detection of transduced cells, and ARC knockdown
was verified by western blotting (Fig. 2a).
Assessment of cell viability
Cell viability was determined using trypan blue exclusion
and the Neubauer counting chamber.
Flow cytometry
For flow cytometry-based caspase activity assays,
approximately 1x105 cells were resuspended in 300 μl
DMEM containing 1 μl of sulfo-rhodamine-conjugated
caspase substrate (Red Caspase Staining Kit, Promokine,
Heidelberg, Germany) and incubated for 0.5–1 h. After
washing the cells twice, red fluorescence was detected
with the flow cytometer (Partec, Muenster, Germany) in
FL-2 channel. The cyanine dye JC-1-(5,5′,6,6′-tetra-
chloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine
iodide) (Life Technologies, Darmstadt, Germany) was
used to measure the breakdown of mitochondrial mem-
brane potential [31]. The harvested cells were resuspended
in DMEM containing 10 μg/ml JC-1 staining dye. The ac-
tivation of mitochondria was observed as an increase in
green fluorescence (FL-1 channel of flow cytometer). The
difference between treated and control cells are reported
as the percent mitochondrial activation.
Fluorescence microscopy
RCC cells were fixed in 3.7% formaldehyde and permea-
bilised in PBST. Nonspecific binding was blocked by in-
cubation with 10% normal goat serum in PBST, followed
by incubation with an anti-ARC polyclonal antibody
(1:500) and an anti-p53 monoclonal antibody (1:500).
For detection, AlexaFluor® 594 goat anti-rabbit IgG and
AlexaFluoir® 514 goat anti-mouse secondary antibodies
(Life Technologies,) diluted 1:500 in blocking buffer were
added to cells. During the subsequent PBST washing
steps, DAPI staining was performed. Finally, slides were
mounted with Vectashield mounting medium (Biozol,
Echingen, Germany) and analysed with a laser scanning
confocal microscope (Zeiss LSM510, Jena, Germany)
equipped with an Argon/2 laser (488 nm, 514 nm), a
Helium-Neon laser (549 nm) and a laser diode (405). The
ZEN 2011 software (Zeiss) was used for data analysis.
Protein extraction and western blotting
Protein extraction and western blotting were performed
according to standard protocols. In short, cell lines were
lysed with lysis buffer (100 mM NaCl, 10 mM Tris–HCl,
pH 7.6, 1 mM EDTA, 1% NP40, protease and phosphatase
inhibitors). The protein concentration of the supernatant
was determined using the Bradford method (Bio-Rad,
Muenchen, Germany). Protein lysate (50 μg) was separated
under denaturing conditions in 10–15% polyacrylamide
gels. The protein was then transferred to a nitrocellulose
membrane. Detection of the proteins was performed using
human-specific monoclonal or polyclonal primary anti-
bodies prior to incubation of the membrane with the
appropriate secondary antibodies (Table 1). Fluorescence
was then visualised with the infrared imager ODYSSEY
(LI-COR, Homburg, Germany), and densitometric analyses
were performed using the Odyssey 2.1.12 Software.
RNA extraction, reverse transcription and real-time
PCR array
To analyse the influence of ARC knockdown on p53-
dependent gene expression, we used the RT2 PCR Profiler
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Array (Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. RT was performed with the RT2 First
Strand kit (Qiagen), and the iCycler iQ5 (Bio-Rad) was
used for quantitative RT-PCR. Data analysis was per-
formed using the ΔΔCt method and the appropriate
software available on the Qiagen website. The results are
presented as scatter blots. The fold-change (2(−ΔΔCt)) was
used to quantify up- or downregulation of gene expression
and was calculated for each gene represented on the array.
A fold change of ±4 was defined as a statistically signifi-
cant change in gene expression.
Results
ARC is overexpressed in the cytoplasm and nuclei of clear
cell RCCs in vivo and in vitro
We previously showed that whole cell lysates from clear
cell RCCs overexpress ARC at the mRNA and protein
level [5]. In the present study, we sought to confirm this
overexpression and to analyse possible differences in the
subcellular localisation of ARC in RCCs compared to
non-neoplastic renal tissue by immunohistochemistry.
Our statistical analysis of ARC expression in 41 clear
cell RCC samples of different tumour stages and grades
(Table 2) and 23 corresponding samples of non-
neoplastic renal tissue using Student’s t-test revealed a
significant increase in cytoplasmic ARC expression in
RCCs of all pathological stages and grades compared to
non-neoplastic renal tissue. However, no significant dif-
ferences were observed between different tumour stages.
In addition, nuclear ARC expression was detectable in
all RCCs, whereas none of the non-neoplastic samples
demonstrated nuclear ARC expression (Fig. 1a).
With regard to tumour grades, a slight but significant
decrease in nuclear as well as cytoplasmic ARC expres-
sion was observed when comparing G1 and G2 with G3
RCCs (Fig. 1a). Based on this result, it is reasonable to
assume that ARC expression plays a more important
role in apoptosis repression in well and moderately
differentiated RCCs compared to poorly differentiated
RCCs, which likely possess additional mechanisms of
apoptosis resistance.
Our analysis of the subcellular distribution of ARC
protein in three RCC cell lines using fluorescent
immunohistochemistry revealed that ARC was strongly
expressed in the cytoplasm and nuclei, with only minor
differences in the distribution pattern between the cell
lines (Fig. 1b).
ARC knockdown neither enhances the induction of p53
inducible genes by topotecan nor induces p53
translocation to the nucleus in RCCs
ARC is strongly expressed in the nuclei of breast cancer
cells that express wild-type (wt) p53, and ARC is known
to inhibit p53-induced apoptosis via a direct interaction
with p53 and its subsequent translocation to the cyto-
plasm [32]. In RCCs, p53 activation is strongly impaired,
although p53 is not mutated in the majority of tumours
[33]. Therefore, we tested whether the nuclear expres-
sion of ARC in RCCs participates in this functional
inhibition of p53.
As shown in Fig. 2a we performed ARC knockdown in
clearCa-12 cells using lentiviral transduction of pGIPZ
shRNAmir constructs. As a control, we used the pGIPZ
non-silencing shRNA plasmid carrying a scrambled
shRNA. Different pGIPZ shRNAmir constructs were
tested to reach the strongest knockdown of ARC. For
further studies we used cells transduced with the
pGIPZ1365 shRNA. ARC knockdown was confirmed by
western blotting (Fig. 2a).
We first treated clearCa-12 cells (expressing wt p53)
with 10 μg/ml topotecan, a classic DNA-damaging drug,
and determined the regulation of p53 target gene
expression in comparison to an untreated control using
a real time PCR array. This analysis revealed that a
change in expression was only observed in 4 of 26 p53
target genes and therefore confirmed that the activation
of p53 was impaired (Fig. 2b). Next, we treated ARC-
knockdown cells with topotecan (10 μg/ml) and compared
the regulation of p53 target genes between these 2 groups.
Using this approach, no significant differences in the in-
duction of p53-target genes between ARC-knockdown
and control cells were detected (Fig. 2b). These results
suggest that nuclear ARC expression in RCCs does not
participate in the regulation of p53-dependent gene
expression.
Furthermore, comparison of the subcellular localisation
of p53 in the ARC-knockdown and control clearCa-12
cells by fluorescent immunohistochemistry showed no
differences (Fig. 2c). Thus, ARC knockdown did not result
in translocation of p53.
In addition to ARC, RCCs express anti- and pro-apoptotic
Bcl-2 family members of all functional groups
ARC is known to inhibit the mitochondrial pathway of
apoptosis by interacting with Bad, Bax and Puma, which
are pro-apoptotic members of the Bcl-2 family [18, 19].
Thus, it is reasonable to assume that ARC cooperates
Table 2 Clear Cell RCC samples
M F G1 G2 G3
N 14 9 1 31 9
pT1 9 6 1 12 2
pT2 6 6 0 9 3
pT3 11 3 0 10 4
Forty one clear cell RCC samples of different tumour stages (pT) and grades
(G) and 23 corresponding samples of non-neoplastic renal tissue (N) were used
to determine the intensity and subcellular localisation of ARC protein expression
by immunohistochemistry. M =male, F = female
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with the anti-apoptotic members of the Bcl-2 family in
protecting the mitochondria by lowering the availability
of these pro-apoptotic Bcl-2 family members. Therefore,
we investigated the expression of ARC as well as
multiple pro- and anti-apoptotic Bcl-2 family members
in 7 RCC cell lines.
The results demonstrate that ARC is stongly expressed
in all RCC cell lines, whereas expression of the antiapop-
totic Bcl-2 famlily members (Bcl-2, Bcl-xl, Bcl-w and
Mcl-1) differs between the cell lines, with a strong ex-
pression of Bcl-xl in clearCa-3, −5, −7, and −11 as well
as Mcl-1 in clearCa-11 as compared to the other RCC
Fig. 1 Expression of ARC in clear cell RCCs and RCC cell lines. a ARC was strongly overexpressed in the cytoplasm of clear cell RCCs (1) compared
to non-neoplastic renal tissue (2), as determined by immunohistochemistry. Furthermore, nuclear ARC expression was only detectable in RCCs
and not in non-neoplastic tissue. For semiquantitative analysis of ARC expression cytoplasmatic stainig was scored from 0 to 12 and nuclear
expression was scored from 0 to 4. All values are expressed as the mean ± s.d. *p < 0.05. b ARC was also strongly expressed in the cytoplasm and
nucleus of the RCC cell lines clearCa-6, −3 and −12. Nuclear and cytoplasmic distribution of ARC differed only slightly between the three RCC cell
lines, as determined by fluorescent immunohistochemistry
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cell lines and a weak expression of Bcl-w in all tested cell
lines as well as Bcl-2 and Mcl-1 in clearCa-3 and
clearCa-12, respectively (Fig. 3a). On the other hand,
multiple pro-apoptotic Bcl-2 family members of all func-
tional groups were expressed [34]: effectors (Bax, Bak),
sensitisers (Bid, Bim) and activators (Puma, Bad, Bok).
However, especially the expression of the activators
differed between the cell lines with a clearly detectable
expression of PUMA only in clearCa-3, clearCa-6, and
clearCa-11 and Bok only in clearCa-6, clearCa-7, and
clearCa-11. Nevertheless, at least one member of each
functional group could be detected in each cell line
(Fig. 3b).
RCCs are sensitive towards ABT263-induced apoptosis
The results outlined above propose, that the RCC cell
lines could be “primed for death” and we therefore
treated them with 10 and 20 μM ABT263, an orally bio-
available Bcl-2 antagonist. In accordance with the results
of Zall and co-workers [28], who treated RCCs with
Fig. 2 ARC and p53 in RCC cell lines. a For ARC knockdown by shRNA in clearCa-12 cells, three lentiviral shRNA vectors were tested, and the
shRNA construct pGIPZ 1365 demonstrated the strongest ARC knockdown (approximately 90%) as determined by western blot. b Treatment of
clearCa-12 cells with 10 μg/ml topotecan modulated gene expression of 4 out of 26 p53-regulated genes in control cells and 2 out of 26 p53-
regulated genes in ARC-knockdown cells, as determined using the p53 Signaling Pathway RT2 Profiler PCR Array (Qiagen, Hilden, Germany) after
12 h of topotecan treatment. Direct comparison of topotecan treated ARC knockdown and control clearCa-12 cells showed no significant differences
with regard to the modulation of p53-regulated genes. Genes with a fold-increase in gene-expression greater than 4 are depicted as red points, and
those with a fold-decrease greater than 4 are depicted as green points. c ARC knockdown did not change the subcellular localisation of p53 in RCCs.
Fluorescent immunohistochemistry for p53 in clearCa-12 cells revealed that ARC knockdown did not change the amount of nuclear p53 in ARC
knockdown cells compared to control cells transduced with non-silencing shRNA
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ABT737, a closely related compound to ABT263, all
RCCs were sensitive to ABT263-induced cell death as
determined by cell count (Fig. 3c). The observed
reduction in cell number after 3 and 12 h was due to
the induction of mitochondrial apoptosis in three
arbitrarily selected RCC cell lines, as determined by
caspase-9 activation as well as mitochondrial depolar-
isation (Fig. 3d).
ARC knockdown sensitises RCC cell lines towards extrinsic
(TRAIL-induced) apoptosis
To examine the role of ARC in the inhibition of the
extrinsic apoptotic pathway in RCCs, we compared
the induction of apoptosis following treatment with
100 ng/ml TRAIL in clearCa-12 ARC knockdown
cells and control cells expressing a scrambled shRNA.
Here, ARC knockdown strongly enhanced TRAIL-
Fig. 3 Expression of ARC and Bcl-2 family members and ABT263-induced apoptosis in RCC cell lines. a ARC as well as anti-apoptotic Bcl-2 family
members were expressed in RCC cell lines, but expression intensity differed between these cell lines. Overall, Bcl-2, Bcl-xl and Mcl-1 exhibited the
strongest expression, whereas Bcl-w showed weaker expression. Bcl-2 was not expressed in clearCa-3 cells and Bcl-w was not expressed in
clearCa-12 cells. BCL-A1 could not be detected (not shown). The p53 mutational status of the cell lines were published by our group elsewhere
[39, 40]. b RCC cell lines expressed pro-apoptotic Bcl-2 family members of all functional groups. Sensitisers (Bid, Bim), activators (Puma, Bad, Bok)
and effectors (Bax, Bak) were detectable in all RCC cell lines, also with differences in the intensity of expression, with clear expression of PUMA
only in clearCa-3, clearCa-6 and clearCa-11 and Bok only in clearCa-6, claerCa-7 and clearCa-11. c All RCC cell lines revealed sensitivity towards
ABT263-induced cell death (10 and 20 μM ABT263), as determined by cell count. All values are expressed as the mean ± s.d. *p < 0.05. d In 3
arbitrarily selected cell lines (clearCa-3, −6 and −12) ABT263 (10 μM) induced mitochondrial apoptosis as determined by caspase-9 and
mitochondrial activation (JC-1 stain). All values are expressed as the mean ± s.d. *p < 0.05
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induced caspase-8 (and −3) activation, which indicated
the importance of ARC for the inhibition of TRAIL-
induced extrinsic apoptosis in RCCs. Furthermore, a slight
increase in mitochondrial apoptosis, as determined by
caspase-9 activation, was also observed upon TRAIL
administration (Fig. 4a).
ARC knockdown sensitises RCC cell lines towards intrinsic
(ABT263- and topotecan-induced) apoptosis
To test the hypothesis that ARC cooperates with
anti-apoptotic Bcl-2 family members in inhibiting
mitochondrial apoptosis, ARC knockdown clearCa-12
cells were treated with topotecan as well as ABT263.
Interestingly, ARC knockdown sensitised the RCC
cells towards topotecan- (Fig. 4b) and ABT263-
induced (Fig. 4c) apoptosis by enhancing the activa-
tion of the mitochondrial pathway, as determined by
caspase-9 and caspase-3 activation as well as mito-
chondrial depolarisation. These results confirmed that
the strong expression of ARC in RCCs plays an im-
portant role in inhibiting intrinsic/mitochondrial
apoptosis.
Fig. 4 Knockdown of ARC sensitises clearCa-12 towards TRAIL-, topotecan- and ABT263-induced apoptosis. ARC knockdown clearCa-12 or control
clearCa-12 cells (non-silencing) were treated with (a) TRAIL (100 ng/ml), (b) topotecan (10 μg/ml), or (c) ABT263 (10 μM). ARC knockdown sensitised
clearCa-12 cells against the extrinsic apoptotic pathway induced by TRAIL as determined by caspase-8 and caspase-3 activation. Topotecan and
ABT263 induced mitochondrial apoptosis as determined by caspase-9 and caspase-3 activation respectively mitochondrial activation. Furthermore,
ARC knockdown enhanced caspase-9 activation induced by TRAIL. All values are expressed as the mean ± s.d. *p < 0.05
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Topotecan sensitizes RCC cell lines to ABT-263 induced
apoptosis
Next, we treated clearCa-3, −6, and −12 cells with topo-
tecan (0.1 μg/ml or 10 μg/ml) for 24 h and added 10 μM
ABT263 for the last 3 h of incubation. In concordance
with the observation made by other groups on Etoposide
[28], this co-treatment resulted in a synergistic effect
and strongly enhanced mitochondrial apoptosis, as
determined by mitochondrial depolarisation as well as
caspase-9 activation in clearCa-6 cells. A smaller but
nevertheless synergistic effect on mitochondrial apop-
tosis by topotecan pre-treatment could also be observed
in the other two cell lines, clearCa-12 and clearCa-3
(Fig. 5a).
ARC knockdown in combination with topotecan treatment
synergistically enhances ABT263-induced apoptosis
Based on the results described above, we hypothesised that
a combination of ARC knockdown, which increases the
availability of pro-apoptotic Bcl-2 family members, and
topotecan treatment, would further enhance ABT263-
induced apoptosis. We, therefore, co-treated ARC-
knockdown clearCa-12 cells with topotecan and ABT263
as previously described, and this treatment synergistically
enhanced ABT263-induced apoptosis in comparison to
control clearCa-12 cells (Fig. 5b).
ARC expression is not regulated by topotecan or UO126
Next, we sought to modify ARC expression using chemical
compounds to evaluate possible therapeutic approaches for
downregulating ARC.
It was previously shown in muscle cells that activation
of p53 results in the downregulation of ARC [19]. In
clearCa-12 cells, however, treatment with 10 μg/ml
topotecan was not able to regulate ARC expression at
the protein level (Fig. 6a).
In a previous study using colon cancer cell lines, the
activation of ERK by RAS oncogenes was proposed as a
mechanism responsible for the strong expression of
ARC [35]. Therefore, we treated clearCa-12 cells with
the ERK inhibitor UO126 (50 μM) for 12 and 24 h.
Although this treatment nearly completely abolished
Fig. 5 ARC knockdown further enhances topotecan-induced sensitisation towards ABT263-induced apoptosis. a ClearCa-3, −6 and −12 cells were
treated with 0.1 μg/ml or 10 μg/ml topotecan for 24 h. Co-treatment with 10 μM ABT263 for the last 3 h of the incubation synergistically enhanced
caspase-9 activation as well as mitochondrial depolarisation (JC-1) measured by flow cytometry, compared to single treatment with topotecan or
ABT263. b ClearCa-12 cells transduced with non-silencing shRNA or ARC knockdown shRNA were treated with 10 μg/ml topotecan for 24 h, and 10 μM
ABT263 was added for the final 3 h of incubation. ARC knockdown further enhanced caspase-9 activation as well as mitochondrial depolarisation
following co-treatment compared to cells transduced with non-silencing shRNA. A synergistic effect (SYN) was determined as i1,2≥ (i1 + i2) +20%, \where
i1,2 = effect of co-treatment, i1 = effect of topotecan and i2 = effect of ABT263
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ERK phosphorylation, ARC protein expression was not
altered (Fig. 6b).
Discussion
The resistance of the tumor cells toward apoptosis is a
hallmark in many tumors. Combination therapy targeting
apoptotic pathways (i.e., Bcl-2 inhibition) is a promising
strategy and is currently evaluated in many clinical trials
[1]. Despite marked efforts in therapeutic strategies the
resistance remains a major problem in cancer therapy.
There is a growing interest to find molecular targets by
which apoptosis can be selectively induced in tumor cells.
One of the promising targets is Bcl-2, against which some
inhibitiors have already been approved (i.e., ABT-263,
ABT-199) [23]. Bcl-2 inhibitors showed enhanced efficiacy
in combination with conventional chemotherapeutic
drugs (i.e., paclitaxel, 5-FU, topotecan) but with these
combinations still not all of the tumor cells can be reached
[23, 24]. For this reason, we focused on ARC protein,
which was expressed in all RCC cell lines and tumor
samples, we have investigated so far.
This resistance towards mitochondrial apoptosis has
mainly been attributed to the anti-apoptotic members of
the Bcl-2 family [27, 28, 36, 37]. Cancer cells can evade
apoptosis by the up-regulation of the pro-survival Bcl-2
family proteins such as Bcl-2, Bcl-xl, and Mcl-1 [26].
Controversely, Mcl-1 can be up-regulated by ABT-263
which contributes to ABT-263 resistance in cancer cells.
ABT-263 increases Mcl-1 stability, but the inhibition of
ERK, JNK or Akt activity can sensitise the cancer cells to
ABT-263 [38].
The current study was the first to show that ARC,
which is overexpressed especially in the cytoplasm of RCCs,
strongly participates in this mitochondrial resistance.
Therefore, ARC is a functionally relevant anti-apoptotic fac-
tor in RCCs acting upstream of the Bcl-2 family members
and supporting anti-apoptotic Bcl-2 family members in pre-
venting apoptosis. ARC overexpression could be detected
in a couple of cancer types and cancer cell lines and in
colorectal cancer cells its expression level is correlated in-
versely to apoptosis in response to chemotherapy [3–7, 9].
However, our previous study of ARC expression in
RCCs did not systematically analyse the subcellular lo-
calisation of ARC in RCCs. Here, we refined our analysis
of ARC expression in RCCs in vivo with regard to its
cellular distribution and found that RCCs express ARC
mainly in the cytoplasm, whereas nuclear expression
was observed in a much smaller proportion of tumour
cells in vivo. ARC is also strongly expressed in the cyto-
plasm and nucleus of RCC cell lines, with nuclear and
cytoplasmic distribution of ARC differing only slightly
between three tested cell lines. These results are consist-
ent with the findings of other groups demonstrating
strong ARC expression not only in the cytoplasm but
also in the nuclei of multiple cancer cell lines [5].
ARC inhibits apoptosis on multiple levels and thereby
acts as an upstream apoptosis inhibitor regulating the
extrinsic and intrinsic apoptotic pathways in different
solid tumours. Regarding the intrinsic pathway of apop-
tosis, ARC has been reported to prevent p53 tetrameri-
sation [32], inhibit caspase-2 activation [3], and bind
pro-apoptotic Bcl-2 family members [18, 19]. With
regard to the extrinsic pathway, ARC interacts with
caspase-8 [3]. However, the exact role of ARC in the
inhibition of apoptosis in RCCs has not been evaluated.
Here, we demonstrated that nuclear ARC expression
was of only minor importance for the regulation of p53-
induced apoptosis in RCCs, as RT-PCR array analysis
Fig. 6 ARC is not regulated by topotecan or UO126. a ClearCa-12
cells were treated with topotecan (10 μg/ml) for 12 h and 24 h. At
the protein level (as determined by western blot), no change in ARC
expression was observed. b ClearCa-12 cells were treated with the
ERK1/2 inhibitor UO126 (50 μM) for 12 and 24 h. This treatment
resulted in nearly the complete loss of ERK1/2 phosphorylation.
However, no change in ARC expression could be demonstrated
on protein level by western blot analysis
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revealed that knockdown of ARC did not influence the
regulation of p53 target genes. Furthermore, the overall
regulation of p53 target genes following treatment with
a high concentration of topotecan was weak, with only 4
of 26 p53-target genes regulated. These results show that
p53 activity is strongly impaired in RCCs [33] and this
impaired p53 activation was not due to ARC expression.
In contrast to observations made in breast cancer cell
lines, ARC knockdown in RCC cells did not result in
p53 translocation to the nucleus [14, 32].
In regard to the extrinsic apoptotic pathway, our re-
sults demonstrate that ARC plays an important role in
the inhibition of TRAIL-induced apoptosis in RCCs, in
concordance with other solid tumours. Consequently,
TRAIL-mediated caspase-8 and −3 activation were sig-
nificantly enhanced by ARC-knockdown. Furthermore,
ARC-knockdown slightly enhanced mitochondrial apop-
tosis, providing an initial clue that ARC may also partici-
pate in protecting the mitochondria of RCCs against
apoptotic stimuli. We conclude that, ARC prevents
activation of the apoptotic initiator caspase-8 as well as
activation of the mitochondrial amplification loop.
Our results also indicated that ARC plays an important
role in the impairment of intrinsic apoptosis: mitochon-
drial activation was suppressed and controlled by ARC. In
contrast, ARC-knockdown sensitised RCC cell lines to
mitochondrial apoptosis induced by topotecan and/or
Bcl-2 antagonist ABT-263. In case of ARC knockdown,
assembly of death-inducing signaling complex (DISC) will
be facilitated and spontaneous Bax activation will be
triggered resulting in apoptosis [8, 16]. In conclusion, our
results suggest that ARC expression in RCCs plays a major
role in therapy resistance, even if a targeted drug (i.e.,
Bcl-2 inhibitor) is given.
The increase in mitochondrial apoptosis upon ARC
knockdown was an important finding, as we and others
have previously demonstrated that altered mitochondrial
activation is crucial for the therapy resistance observed
in RCCs [27, 28, 36, 37, 39].
Membrane binded Bcl-2 and Bcl-xl inhibit the release
of many apoptotic proteins from mitochondria (i.e.,
cytochrome c, pro-caspase 3, and apoptosis inducing
factor). Bcl-2, which is overexpressed in most RCCs,
contributes to tumor development and progression. In
addition, Bcl-2 overexpression is correlated with a low
apoptosis rate of tumor cells [1]. ARC functions as an
anti-apoptotic regulator upstream of Bcl-2 family mem-
bers by interacting with and thereby reducing the avail-
ability of pro-apoptotic binding partners of the Bcl-2
family, including Puma, Bax and Bad. Thus, ARC plays a
pivotal role in fine-tuning the apoptotic machinery.
In addition to Puma, Bax, and Bad, all RCC cell lines
expressed pro-apoptotic Bcl-2 family members, includ-
ing Bid, Bim, Bok, and Bak. Although expression levels
of these proteins differed between the tested cell lines,
members of all functional groups (sensitisers, activators,
and effectors) were detectable in each cell line, and
therefore, we termed RCC cell lines “primed for death”
according to the model of Deng et al. [34]. In summary,
these findings provided rationale for the sensitivity of
RCCs towards Bcl-2 inhibitors such as ABT263. In
accordance with previous observations on ABT-737 and
RCCs [28], these “primed for death” cells were all sensi-
tive to ABT-263-induced apoptosis, albeit only to a
certain degree. This limited sensitivity of our RCC cell
lines towards ABT-263 showed some correlation to the
expression profile of anti-apoptotic Bcl-2 family mem-
bers. In all cell lines evaluated, Mcl-1, which is not
inhibited by ABT263 [26], was detected at the protein
level. The ABT-263 binding partners Bcl-2, Bcl-w and
Bcl-xl were also expressed in these cell lines, with the
exception of Bcl-2 in clearCa-3 and Bcl-w in clearCa-12.
Taken together, our findings regarding ARC and Bcl-2
family member expression suggest that the limited
sensitivity of RCCs to Bcl-2 inhibitors, which is
commonly explained by the presence or absence of
pro- and anti-apoptotic Bcl-2 family members them-
selves [27, 28, 36, 37], also depends on other factors
such as ARC interacting with these Bcl-2 family
members. These additional factors can modulate the
sensitivity of cells towards Bcl-2 antagonists, thereby sup-
porting the role of anti-apoptotic Bcl-2 inhibitors in pro-
tecting the mitochondria from apoptotic signals.
Moreover, the downregulation of ARC expression likely in-
creased the availability of pro-apoptotic binding partners,
including Bax, Bad and Puma, at the mitochondria
and thereby enhanced mitochondrial apoptosis.
Due to its important role in inhibiting extrinsic and
intrinsic apoptosis, we sought to downregulate the ex-
pression of ARC in our RCC cell lines using chemical
compounds to evaluate new approaches for targeting ARC
overexpression therapeutically. However, our attempts to
modulate ARC expression by mechanisms previously
described in other cell lines were not successful in RCC
cells; neither topotecan, as a classic chemotherapeutic
compound [19], nor the ERK-inhibitor UO126 [35] were
able to downregulate ARC expression, although both
mechanisms were previously described to inhibit ARC
gene expression in myocardial and colon cancer cell lines,
respectively. Thus, the precise cellular mechanism respon-
sible for the strong ARC expression in RCCs needs to be
determined in further experiments.
Next, we tried to further enhance ABT-263-induced
apoptosis in RCCs by a pre-treatment with topotecan. Al-
though the synergistic enhancement of ABT263-induced
apoptosis by topotecan was strongest in clearCa-6, a syn-
ergistic enhancement of mitochondrial apoptosis could
also be observed in clearCa-3 and clearCa-12.
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As a result, both strategies – indirectly increasing the
availability of pro-apoptotic Bcl-2 family members by
ARC knockdown as well as topotecan pre-treatment – led
to an increased sensitivity of the RCC cell lines towards
ABT263-induced apoptosis.
Therefore, it was reasonable to attempt a combination
of these strategies to further enhance anti-Bcl-2 treat-
ment sensitivity. In fact, this strategy synergistically
enhanced ABT263-induced apoptosis in all cell lines,
which suggests that ARC supports the function of anti-
apoptotic Bcl-2 family members in preventing mitochon-
drial apoptosis in RCC cell lines.
Conclusion
In conclusion, our study demonstrates that the constitutive
overexpression of ARC in RCCs may can explain their
well-known resistance to multiple therapeutic strategies
that are directed against the extrinsic and intrinsic path-
ways of apoptosis. Thus, targeting the ARC protein may be
a promising new therapeutic approach for RCCs. However,
future experiments should address how this overexpression
could be overcome to reduce the resistance of RCCs.
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